Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Alternext  >  Diaxonhit    ALEHT   FR0013240934

DIAXONHIT (ALEHT)
Mes dernières consult.
Most popular
Delayed Quote. Delayed  - 09/22 05:35:15 pm
5.76 EUR   +0.70%
 SummaryQuotesChartsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
09/18/2017 09/19/2017 09/20/2017 09/21/2017 09/22/2017 Date
5.44(c) 5.45(c) 5.45(c) 5.72(c) 5.76(c) Last
13 671 5 007 13 305 31 438 30 301 Volume
+2.45% +0.18% 0.00% +4.95% +0.70% Change
More quotes
Financials (€)
Sales 2017 46,8 M
EBIT 2017 -4,00 M
Net income 2017 -5,40 M
Debt 2017 3,40 M
Yield 2017 -
Sales 2018 49,9 M
EBIT 2018 0,60 M
Net income 2018 -1,40 M
Debt 2018 2,20 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 1,25x
EV / Sales2018 1,15x
Capitalization 55,2 M
More Financials
Company
Diaxonhit engages in the research and commercialization of diagnostic products.Its portfolio consists of proprietary diagnostic products in the following areas: transplantation, infectious diseases and cancer diagnosis.The company markets Tetanus Quick Stick used for the evaluation of patient's... 
More about the company
Latest news on DIAXONHIT

- No features available -

More news
Sector news : Biotechnology & Medical Research - NEC
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
09/07 New AstraZeneca, Amgen drug looks strong rival in severe asthma
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
09/05BRIEF-Diaxonhit announces ?definitive acquisition of Genbio?  
2016Diaxonhit enrolls first patients in cost-utility analysis study for AlloMap $.. 
2016Diaxonhit reports FY15 results  
2016BRIEF-Diaxonhit and CareDx successfully transfer AlloMap test to Europe  
2015Diaxonhit $aleht provides update on HIV @Aurgalys Estimated price : 1,62€
2
More tweets
Qtime:6
Chart DIAXONHIT
Duration : Period :
Diaxonhit Technical Analysis Chart | ALEHT | FR0013240934 | 4-Traders
Technical analysis trends DIAXONHIT
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 9,70 €
Spread / Average Target 68%
EPS Revisions
Managers
NameTitle
Jean-Michel Carle Chairman-Management Board
Jean-Pierre Hermet Chairman-Supervisory Board
Hervé Duchesne de Lamotte Chief Financial Officer
Michel Picot Member-Supervisory Board
Danièle Guyot-Caparros Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
DIAXONHIT-7.74%66
INCYTE CORPORATION14.56%23 351
QUINTILES IMS HOLDINGS INC24.44%20 370
LONZA GROUP57.01%19 634
CELLTRION, INC.--.--%15 568
ALNYLAM PHARMACEUTICALS, INC.204.06%10 439